To order this detailed 380+ page report, please visit this link
Key Inclusions
- A detailed assessment of the current market landscape of psychedelic therapeutics, providing information on phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, type of psychedelic substance, origin of psychedelic substance, target therapeutic area route of administration (intranasal, intravenous, oral, sublingual, topical and transdermal), dosing frequency (single dose, twice a week, once in two months and others). In addition, it includes information on drug developer(s), highlighting year of their establishment, company size, and location of headquarters.
- Tabulated profiles of prominent psychedelic therapeutics developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
- An in-depth analysis of completed, ongoing and planned clinical studies of various psychedelic therapeutics, based on the various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population and geographical distribution of trials, study design, leading industry (in terms of number of trials conducted), study focus, target therapeutic area, key geographical regions.
- An insightful analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics, based on relevant parameters, such as type of psychedelic substance, trial phase, target therapeutic area and location of the trial.
- A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
- A detailed analysis of nearly 550 grants that have been awarded to research institutes engaged in psychedelic therapeutics projects, in the period between 2015 and 2020 (till May), including analysis based on important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, grant funding mechanism, study section involved, and recipient organizations. In addition, it highlights popular psychedelic therapeutics, popular funding institute centers, prominent program officers, and popular recipient organizations.
- An analysis of the partnerships that have been established in the recent past (2017-2020 till May), covering acquisitions and mergers, licensing agreements, product development agreements, research agreements, research and development agreements, clinical trial agreements, joint venture agreements and other relevant types of deals.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2017-2020, based on parameters, such as year of merger and acquisition, type of acquisition, geographical location of the acquirer and the acquired company, and key value drivers. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Target Disease Indication
- Anxiety and Depression
- Trauma
- Pain Disorder
- Sleep related Disorder
- Origin of Psychedelic Substance
- Natural
- Synthetic
- Type of Psychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
- Route of Administration
- Oral
- Intranasal
- Sublingual
- Key Geographies
- North America
- Europe
- Asia-Pacific
To request sample pages, please visit this link
Key Questions Answered
- Who are the leading industry players in this domain?
- What are the key clinical conditions addressed by psychedelic therapeutics?
- Who are the key opinion leaders from renowned academic and research institutes that can assist in driving development efforts for psychedelic therapeutics?
- Which partnership models are commonly adopted by stakeholders engaged in this industry?
- Which are the most active trial sites where clinical studies focused on psychedelic therapeutics are being conducted?
- Which factors are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
- Endocannabinoid System Targeted Therapeutics Market, 2020-2030
- Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019
- Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights
- Neoantigen Targeted Therapies Market, 2019-2030
- Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]
Roots Analysis has done a detailed study on “Global Psychedelic Therapeutics Market, 2020-2030”, covering key aspects of the industry and identifying potential future growth opportunities To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this link Key Market Insights Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybinThe pipeline features product candidates based on a variety of psychedelic drug classes, which are being investigated for a wide range of target disease indications, and having different routes of administrationFrom a global perspective, this industry is anticipated to evolve significantly over the next few years as federal / regional regulators in different nations are gradually convinced of the clinical significance of this product classSeveral organizations, having realized the untapped opportunity within this emerging segment of psychedelic therapeutics, have awarded grants of over USD 275 million across 500+ instances between 2015-2020Several trials evaluating various psychedelic compounds against a wide range of therapeutic indication have been registered in the recent pastThe growing interest is also reflected in the partnership activity since 2017; a number of different types of deals involving various drug classes have been established across multiple geographiesPresently, North American companies are actively consolidating their indigenous presence through strategic acquisitions; key value drivers behind such deals include both portfolio and geographical expansionA number of eminent scientists from renowned universities have emerged as key opinion leaders in this domain, owing to their active involvement in clinical development efforts related to interventions based on psychedelicsFuture market size, based on revenue reported from the sales of marketed and late stage psychedelic-based therapies, is anticipated to be distributed across different therapeutic areas and key geographical regions For more information, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html Table of Contents PREFACE1.1.
Clinical Trial Sites in North America7.3.1.1.1.
Popular Funding Institute Centers: Analysis by Number of Grants9.3.15.
Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-203012.5.2.
Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-203012.8.2.
Interview Transcript: Andrew Chadeayne, Founder & Chief Executive Officer 14.3. iX Biopharma14.3.1.
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.
Europe is currently regarded as a key manufacturing hub for microbial biologicsThere are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%).
On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.
Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
The global Hydrazine Hydrate Market was valued at USD 395.7 Million in 2016 and is projected to reach USD 531.1 Million by 2022, at a CAGR of 5.5% from 2017 to 2022.Browse 147 Market Data Tables and 36 Figures spread through 159 Pages and in-depth TOC on "Hydrazine Hydrate Market”.Polymerization & blowing agents is estimated to be the largest application segment of the global hydrazine hydrate market between 2017 and 2022Among various applications, polymerization & blowing agents is estimated to be the largest application of the global hydrazine hydrate market.
In addition, there are several other hydrazine-based chemical blowing agents such as benzene and toluenesulfonylhydrazide, which are used in low temperature applications.Speak to our analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=172748863New product launch was the key strategy adopted by major players to enhance their presence in the global hydrazine hydrate market between 2014 and 2016.
This strategy accounted for a major share of all development strategies adopted by leading players during the above-mentioned period.
The company operates through three business segments, namely, high performance materials, industrial specialties, and coating solutions.
The company has a widespread presence and distribution networks in Asia Pacific, Europe, Middle East & Africa, and the Americas.Lonza is also one of the major producers of hydrazine hydrate and supplies various concentration grades such as 35%, 51.2%, 54.4%, 64%, 98%, and 99%.
It operates its business through two segments namely, Pharma and Specialty Ingredients segments.
